$0.74
2.49% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US1897631057
Symbol
CODX
Sector
Industry

Co-Diagnostics, Inc. Stock price

$0.72
-0.28 27.80% 1M
-0.33 31.24% 6M
-0.03 3.73% YTD
-0.48 39.83% 1Y
-6.15 89.49% 3Y
-2.01 73.55% 5Y
-5.09 87.57% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
-0.01 1.77%
ISIN
US1897631057
Symbol
CODX
Sector
Industry

Key metrics

Market capitalization $23.05m
Enterprise Value $-12.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.46
EV/Sales (TTM) EV/Sales -2.93
P/S ratio (TTM) P/S ratio 5.51
P/B ratio (TTM) P/B ratio 0.36
Revenue growth (TTM) Revenue growth -10.36%
Revenue (TTM) Revenue $4.18m
EBIT (operating result TTM) EBIT $-43.14m
Free Cash Flow (TTM) Free Cash Flow $-26.84m
Cash position $37.66m
EPS (TTM) EPS $-1.35
P/S forward 5.57
EV/Sales forward negative
Short interest 0.86%
Show more

Is Co-Diagnostics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Co-Diagnostics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Co-Diagnostics, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Co-Diagnostics, Inc.:

Hold
100%

Financial data from Co-Diagnostics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.18 4.18
10% 10%
100%
- Direct Costs 5.04 5.04
71% 71%
121%
-0.87 -0.87
151% 151%
-21%
- Selling and Administrative Expenses 19 19
9% 9%
445%
- Research and Development Expense 22 22
4% 4%
535%
-42 -42
4% 4%
-1,000%
- Depreciation and Amortization 1.33 1.33
6% 6%
32%
EBIT (Operating Income) EBIT -43 -43
4% 4%
-1,032%
Net Profit -41 -41
3% 3%
-988%

In millions USD.

Don't miss a Thing! We will send you all news about Co-Diagnostics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Co-Diagnostics, Inc. Stock News

Neutral
PRNewsWire
29 days ago
SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. Live from MarketSite is ...
Neutral
PRNewsWire
about 2 months ago
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platfo...
Neutral
Seeking Alpha
3 months ago
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C.
More Co-Diagnostics, Inc. News

Company Profile

Co-Diagnostics, Inc. engages in the development, manufacture, and marketing of diagnostics technology. It offers design services, vector control, equipment, diagnostic, and research solutions. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Dwight Egan
Employees 155
Founded 2013
Website www.codiagnostics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today